Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Advertisement
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Jonathan Friedberg, MD, MMSc, discusses the trial and its implications for the field.
A first-in-human phase I trial will evaluate escalating doses of BITT2101 in patients with non-Hodgkin lymphoma.
The application for the approval of epcoritamab is based on results from the phase I/II EPCORE NHL-1 trial.
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
The phase II study previously showed pembrolizumab had effective antitumor activity and acceptable safety in R/R PMBCL.
Advertisement
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
The FDA approves the first bispecific antibody for relapsed/refractory DLBCL.
A new global, multicenter study is enrolling patients with newly diagnosed diffuse large B-cell lymphoma.
The study compared axicabtagene ciloleucel with standard‑of‑care therapy in patients with relapsed or refractory LBCL.
Dr. Nastoupil discusses findings from TRANSFORM subgroup analyses.
CAR T-cell therapy with lisocabtagene maraleucel resulted in survival benefits for patients with relapsed or refractory.
Dr. Dickinson and colleagues presented the research at the 2023 American Society of Clinical Oncology Annual Meeting.
Targeted induction immunochemotherapy with ibrutinib or lenalidomide and R-MPV is feasible, according to the researchers.
ZUMA-23 will be the first phase III randomized controlled study to evaluate CAR-T as a frontline regimen for any cancer.
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory DLBCL, High-Grade BCL
The accelerated approval follows the FDA granting priority review to the Biologics License Application.
This episode provides listeners with DLBCL management strategies and an overview of the latest research in the field.
Drs. Vijenthira and Prica discuss their study and why its results differed from a similar study published in late 2022.
The approval is based on results from the pivotal phase III TRANSFORM trial.
The FDA approval of pola-R-CHP for first-line treatment of DLBCL is based on pivotal data from the phase III POLARIX trial.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.